Product
Tegoprazan
Aliases
K-CAB Tab. 25mg, Tegoprazan 12.5mg, Tegoprazan 25mg, Tegoprazan 25 mg (1 other aliases)
15 clinical trials
6 indications
Indication
Helicobacter pylori infectionIndication
HealthyIndication
Erosive EsophagitisIndication
Peptic UlcerIndication
Gastroesophageal Reflux DiseaseIndication
Laryngopharyngeal Reflux DiseaseClinical trial
A Multi-center, Randomized, Double-blind, Double-dummy Phase III Clinical Study to Evaluate the Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter PyloriStatus: Completed, Estimated PCD: 2023-09-30
Clinical trial
Phase 1 Clinical Trial to Explore Pharmacokinetics, Pharmacodynamics and Safety of Tegoprazan 12.5 mg After Oral Administration in Healthy SubjectsStatus: , Estimated PCD: 2024-07-31
Clinical trial
A Randomized, Double-Blind, Active-controlled, Multi-center, Therapeutic Exploratory Study to Evaluate the Safety and Efficacy of a Standard Triple Therapy With Tegoprazan (by Dose) in H. Pylori Positive PatientsStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase 3, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tegoprazan 25 mg for the Prevention of Peptic Ulcer Disease in Patients on Continuous Long-term Treatment With NSAIDsStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase 3, Double-blind, Randomized, Active-controlled Study to Evaluate the Safety and Efficacy of Tegoprazan as Maintenance Therapy in Patients With Healed Erosive EsophagitisStatus: Completed, Estimated PCD: 2021-06-23
Clinical trial
A Randomized, Open-label, Three-period, Multiple Dosing Crossover Clinical Trial to Evaluate the Influence of Tegoprazan on the Pharmacodynamics of Clopidogrel in Healthy SubjectsStatus: Not yet recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Multicenter, Double-blind, Randomized, Active-controlled Phase 4 Study to Evaluate the Efficacy and Safety of Tegoprazan in GERD Patients With Nighttime HeartburnStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
An Open-label, Fixed-sequence Study to Evaluate the Drug-drug Interactions Between Tegoprazan Tablets and Bismuth Potassium Citrate Capsules, Amoxicillin Capsules, and Clarithromycin Tablets in Healthy SubjectsStatus: Completed, Estimated PCD: 2023-04-28
Clinical trial
An Open-label, Randomized, Crossover Study to Evaluate the Pharmacokinetic and Pharmacodynamic Interaction Between Tegoprazan and Novel Oral Anticoagulants (NOACs) After Multiple Oral Dosing in Healthy VolunteersStatus: Completed, Estimated PCD: 2023-07-17
Clinical trial
Efficacy and Safety of a Triple Eradication Scheme for Helicobacter Pylori Based on Amoxicillin 1g + Clarithromycin 500 mg and Tegoprazan 50 mg vs Amoxicillin 1g + Clarithromycin 500 mg and Esomeprazole 40 mg Twice a Day for 14 DaysStatus: Not yet recruiting, Estimated PCD: 2024-11-29
Clinical trial
Comparison of the Efficacy of Tegoprazan-containing Versus Esomeprazole-containing Dual Therapy for Helicobacter Pylori Eradication: a Prospective, Multicenter, Randomized Controlled Study （SHARE2301）Status: Recruiting, Estimated PCD: 2023-10-01
Clinical trial
The Efficacy of Potassium-competitive Acid Blocker (P-CAB) in Patients With Laryngopharyngeal Reflux Disease: a Double- Blind, Randomized, Placebo-controlled Pilot StudyStatus: Completed, Estimated PCD: 2021-12-30
Clinical trial
14-day High-dose Tegoprazan Double Therapy Versus Bismuth Quadruple Therapy in First-line Treatment of Helicobacter Pylori Infection: a Prospective, Randomized, Controlled StudyStatus: Not yet recruiting, Estimated PCD: 2023-12-20
Clinical trial
The Efficacy of Bismuth-containing Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection in 10 Days and 14 Days: a Prospective, Randomized, Controlled StudyStatus: Not yet recruiting, Estimated PCD: 2023-10-31
Clinical trial
Efficacy of Tegoprazan-containing Sequential Therapy Compared to Proton Pump Inhibitor-based Eradication in South Korea, a Region With High Antimicrobial Resistance: A Prospective Randomized Single Tertiary Center StudyStatus: Recruiting, Estimated PCD: 2024-12-12